Daiichi Sankyo has appointed Dr Antoine Yver to the newly-created position of global head, oncology research and development.
Reporting directly to Dr Glenn Gormley, Daiichi Sankyo’s president and global head of research and development, Dr Yver will oversee the entirety of the firm’s global research and development in the oncology therapeutic area.
Dr Gormley said: “Antoine brings a strong track record of extensive scientific leadership in many facets of global oncology pharmaceutical research and development along with tremendous passion for science and patients.
“We are confident that Antoine will provide great leadership and strategic insights in this new role, which underscores Daiichi Sankyo’s commitment to the fight against cancer.”
Dr Yver moves from AstraZeneca, where he has served as senior vice president and head of oncology global medicines development as well as leading its global medicines development in China since 2012.
Prior to this, he has held senior management roles in oncology research at Aventis, Johnson & Johnson and Schering-Plough.
Dr Yver said: “I’m excited to join such a respected company and further build its presence in this important field.
“I have been most impressed by the quality of science at Daiichi Sankyo and the company’s strong commitment towards becoming an innovator in bringing new therapeutic options to people living with cancer.”